Option chain shows key data for Huntington Bancshares's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Huntington Bancshares.

Huntington Bancshares (NASDAQ:HBANP) Stock, Option Chain

Huntington Bancshares

Huntington is a regional us bank with around $200 billion in assets (as of September 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.

Biotech

Long Ideas

News

Insider Trades

Markets

Trading Ideas

General

HBAN

HBANP

SHLD

3 Biotech Companies Insiders Keep Buying

Eurozone

Futures

Global

Pre-Market Outlook

GOOGL

TRIV

US Stock Futures Surge Ahead Of Beige Book, Bank of America Earnings 

Intraday Update

Movers

DXCM

EDUC

HOMB

RDEN

Stocks That Created New 52-Week Highs (DXCM, EDUC, RDEN, HOMB, HBANP)

Huntington Bancshares Incorporated - Depositary Shares 4.500% Series H Non-Cumulative Perpetual Preferred Stock

Huntington Bancshares Inc

<ul>
<li>Insiders continue to snap up seeming bargains, even with the markets on the rise.</li>
<li>Three biotech companies saw notable insider purchases recently.</li>
<li>Strong insider buying is often considered a positive sign for investors, particularly during volatile periods. </li>
</ul>
While the markets may be up from their lows in February and near breakeven for the year to date, it hasn't stopped insiders from taking advantage of seeming bargains to bolster their positions. This is even true in industries that have had a rough time of late, such as biotechnology. It is a further sign that some see good things ahead.
Conventional wisdom says insiders and 10 percent owners really only buy shares of a company for one reason &ndash; they believe the stock price will rise and they want to profit from it. Companies as diverse as struggling retailers J C Penney Company Inc (NYSE: <a class="ticker" href="/stock/jcp#NYSE">JCP</a>) and Sears Holdings Corp (NASDAQ: <a class="ticker" href="/stock/shld#NASDAQ">SHLD</a>), regional bank Huntington Bancshares Incorporated (NASDAQ: <a class="ticker" href="/stock/hban#NASDAQ">HBAN</a>) (NASDAQ: <a class="ticker" href="/stock/hbanp#NASDAQ">HBANP</a>) and consumer products maker Newell Rubbermaid Inc. (NYSE: <a class="ticker" href="/stock/nwl#NYSE">NWL</a>) have seen insiders come to the buy window in a big way, but here we focus on three biotech companies with repeat buys.
<h3>OvaScience</h3>
The chief executive officer recently scooped up a more than 162,000 shares of OvaScience Inc (NASDAQ: <a class="ticker" href="/stock/ovas#NASDAQ">OVAS</a>) in two transactions, at share prices of $7.50 and $8.05, respectively. That cost him more than $1.23 million. The stock has lost about 83 percent of its value in the past year.
The market cap of this global company focused on developing fertility treatments now is only about $200 million. The share price is down more than 23 percent since the beginning of the year to the close at $7.47 on Wednesday. The Nasdaq was down less than 5 percent in that time.
<bzrelatedlink>Related Link: <a href="http://www.benzinga.com/trading-ideas/long-ideas/16/03/7715462/fitbit-coca-cola-lead-list-of-most-notable-insider-trades-of-">Fitbit, Coca-Cola Lead List Of Most Notable Insider Trades Of Past Week</a></bzrelatedlink>
<h3>Opko Health</h3>
The chairman continues to buy batches of shares periodically, as he has done for well more than a year. In the past week, he added more than 53,000 Opko Health Inc. (NYSE: <a class="ticker" href="/stock/opk#NYSE">OPK</a>) shares, while the chief technology officer bought 6,000 shares. At between $9.82 and $10.21 per share, those purchases totaled more than $592,000.
This Miami-based healthcare company has a market cap near $5.6 billion, and it recently posted a positive earnings surprise. Note that short interest is more than 20 percent of the total float. Shares closed most recently at $10.23, up less than 2 percent year to date.
<h3>Seattle Genetics</h3>

A director added almost 507,000 shares to his stake in this biotech company. At between $32.03 and $33.10 per share, the total for the purchases came to about $22.55 million. Note that this same director also <a href="http://www.benzinga.com/general/biotech/16/03/6767726/3-biotech-companies-with-recent-large-insider-buying">bought $9.3 million</a> worth of shares earlier in the month, and his stake is now over 37.4 million shares.
Seattle Genetics, Inc. (NASDAQ: <a class="ticker" href="/stock/sgen#NASDAQ">SGEN</a>) has a $4.4 million market cap. The stock closed Tuesday at $32.52 a share, after rising more than 18 percent from the 52-week low in February. Since the first of the year, however, shares are still down more than 27 percent.
Disclosure: At the time of this writing, the author had no position in the mentioned equities.
Image Credit: <a href="https://pixabay.com/en/laboratory-beakers-science-1149152/">Public Domain</a>

Pre-open movers

US stock futures jumped in early pre-market trading, ahead of earnings from Bank of America (NYSE: <a class="ticker" href="/stock/bac#NYSE">BAC</a>) and Google (NASDAQ: <a class="ticker" href="/stock/googl#NASDAQ">GOOGL</a>). The Housing starts report for March will be released at 8:30 a.m. ET, while industrial production data for March will be released at 9:15 a.m. ET. The Federal Reserve will release its latest Beige Book report at 2:00 p.m. ET. Futures for the Dow Jones Industrial Average surged 69 points to 16,274.00, while the Standard &amp; Poor's 500 index futures rose 8.30 points to 1,847.90. Futures for the Nasdaq 100 index gained 18.50 points to 3,509.75.

A Peek Into Global Markets

 
European markets were higher today, with the Spanish Ibex Index surging 1.11%, London's FTSE 100 index gaining 0.33% and STOXX Europe 600 Index jumping 0.74%. German DAX 30 index climbed 0.79% and French CAC 40 Index rose 0.85%. Italy's trade surplus widened to EUR2.6 billion ($3.59 billion) in February, from EUR1.0 billion in the year-ago month. UK's unemployment declined to 6.9% in the three months to February. The European Union's consumer prices rose 0.9% in March from February.

Asian markets ended mostly higher today. Japan's Nikkei Stock Average surged 3.01%, Hong Kong's Hang Seng Index rose 0.11%, China's Shanghai Composite gained 0.17% and India's BSE Index dropped 0.92%.
 
Broker Recommendation

Analysts at Imperial Capital upgraded Goodrich Petroleum (NYSE: <a class="ticker" href="/stock/gdp#NYSE">GDP</a>) from “in-line” to “outperform.” The target price for Goodrich Petroleum has been raised from $13 to $33. 

Goodrich Petroleum's shares closed at $24.34 yesterday.

Breaking news 


<ul><li> Huntington Bancshares Incorporated announced that the board of directors has declared a quarterly cash dividend on its 8.50% Series A Non-Cumulative Perpetual Convertible Preferred Stock (NASDAQ: <a class="ticker" href="/stock/hbanp#NASDAQ">HBANP</a>) of $21.25 per share. To read the full news, <a href="http://www.benzinga.com/pressreleases/14/04/b4474257/huntington-bancshares-incorporated-declares-quarterly-cash-dividend-on-">click here. </a></li>
 
<li> TriVascular Technologies (NASDAQ: <a class="ticker" href="/stock/triv#NASDAQ">TRIV</a>) today announced the pricing of its initial public offering of 6,500,000 shares of its common stock at a public offering price of $12.00 per share. To read the full news, <a href="http://www.benzinga.com/pressreleases/14/04/g4473574/trivascular-technologies-inc-announces-pricing-of-initial-public-offeri">click here.</a></li>
 
<li> Credit Suisse Group AG (NYSE: <a class="ticker" href="/stock/cs#NYSE">CS</a>) reported a drop in first-quarter profit. To read the full news, <a href="http://www.benzinga.com/news/earnings/14/04/4474205/credit-suisse-posts-lower-q1-profit">click here.</a></li>
 
<li> Dr Reddy's Laboratories (NYSE: <a class="ticker" href="/stock/rdy#NYSE">RDY</a>) announced today that it has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA® (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food &amp; Drug Administration (USFDA). To read the full news, <a href="http://www.benzinga.com/pressreleases/14/04/b4473742/dr-reddys-announces-the-launch-of-eszopiclone-tablets-c-iv">click here.</a></li>
</ul>

Huntington Bancshares Incorporated announced that the board of directors 
 has declared a quarterly cash dividend on its 8.50% Series A 
 Non-Cumulative Perpetual Convertible Preferred Stock (NASDAQ: <a class="ticker" href="/stock/hbanp#NASDAQ">HBANP</a>) of 
 $21.25 per share. The dividend is payable July 15, 2014, to shareholders 
 of record on July 1, 2014. The board of directors also declared a 
 quarterly cash dividend on its Floating Rate Series B Non-Cumulative 
 Perpetual Preferred Stock (CUSIP#: 446150500) of $7.31612676 per share 
 (equivalent to $0.1829032 per depositary receipt share). The dividend is 
 payable July 15, 2014, to shareholders of record on July 1, 2014.
 About Huntington
 Huntington Bancshares Incorporated is a $60 billion asset regional bank 
 holding company
 <a href="http://www.benzinga.com/pressreleases/14/04/b4474257/huntington-bancshares-incorporated-declares-quarterly-cash-dividend-on-">See full press release</a>

Dividends

Huntington Bancshares Announces Quarterly Cash Dividend on Its Series A and B Preferred Stocks 

DexCom, Inc (NASDAQ: <a class="ticker" href="/stock/dxcm#NASDAQ">DXCM</a>) shares jumped 4.77% to create a new 52-week high of $9.66. DXCM was upgraded by Soleil from “hold” to “buy.”
Educational Development Corporation (NASDAQ: <a class="ticker" href="/stock/educ#NASDAQ">EDUC</a>) shares rose 2.02% to $6.05, creating a new 52-week high. EDUC reported record sales and earnings for the quarter ended November 30, 2009, with net revenues of $10,016,400 and net earnings of $925,100, as compared to $9,388,200 and $649,500, respectively, for the same period last year.
Elizabeth Arden, Inc (NASDAQ: <a class="ticker" href="/stock/rden#NASDAQ">RDEN</a>) shares rose 3.83% to $16.25, creating a new 52-week high. RDEN has been upgraded by Sun Trust Rbsn Humphrey from “neutral” to “buy.”
Home BancShares, Inc (NASDAQ: <a class="ticker" href="/stock/homb#NASDAQ">HOMB</a>) shares rose 1.24% to $25.23, creating a new 52-week high. Home BancShares operates as a multibank holding company that provides various commercial and retail banking and related financial products, as well as services to businesses, real estate developers, investors, individuals and municipalities.
Huntington Bancshares (NASDAQ: <a class="ticker" href="/stock/hbanp#NASDAQ">HBANP</a>) shares rose 1.36% to $897, creating a new 52-week high. HBANP has added another member to its board, Richard Neu, as a director, with strong ties to the Cleveland market.
<a href="http://www.benzinga.com/trading-ideas">Check more Trading Ideas</a>

Huntington Bancshares Incorporated (HBAN) Q1 2024 Earnings Call Transcript

Huntington Bancshares Incorporated 4.500% DEP PFD H declares $0.2812 dividend

Huntington Bancshares Incorporated 4.500% DEP PFD H goes ex dividend Monday

Huntington Bancshares Incorporated 2024 Q2 - Results - Earnings Call Presentation

Huntington Bancshares Incorporated (HBAN) Q2 2024 Earnings Call Transcript

Huntington Bancshares: Big Improvements In Q2, 52-Week Highs

Huntington Bancshares Incorporated 4.500% DEP PFD H declares $0.2182 dividend

TCW Relative Value Mid Cap Fund Q2 2024 Commentary

Huntington Bancshares Incorporated (HBAN) Q3 2024 Earnings Call Transcript

ACGL

ACGLN

ACGLO

ACHC

AKAM

APOS

CPAY

FLEX

HBANL

HBANM

MSCI

Press Releases

Huntington Bancshares Incorporated Declares Quarterly Cash Dividends On Its Common and Preferred Stocks

Comments

Huntington Bancshares

Huntington Bancshares (HBANP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga